EcoDrugPlus

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSSBOG00000026033
Gene Symbol: MLST8
2 Cross references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nad(P)h Quinone Dehydrogenase 1

Ensembl ID : ENSSBOG00000026784
Gene Symbol: NQO1
2 Cross references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nadph Oxidase 4

Ensembl ID : ENSSBOG00000031083
Gene Symbol: NOX4
2 Cross references
151 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nfe2 Like Bzip Transcription Factor 2

Ensembl ID : ENSSBOG00000022740
Gene Symbol: NFE2L2
2 Cross references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Npc1 Like Intracellular Cholesterol Transporter 1

Ensembl ID : ENSSBOG00000031878
Gene Symbol: NPC1L1
2 Cross references
189 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Pim-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSSBOG00000020040
Gene Symbol: PIM1
2 Cross references
244 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Pim-2 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSSBOG00000013515
Gene Symbol: PIM2
2 Cross references
115 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Pim-3 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSSBOG00000025009
Gene Symbol: PIM3
2 Cross references
217 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Rar Related Orphan Receptor C

Ensembl ID : ENSSBOG00000022092
Gene Symbol: RORC
2 Cross references
382 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Rela Proto-Oncogene, Nf-Kb Subunit

Ensembl ID : ENSSBOG00000035520
Gene Symbol: RELA
2 Cross references
199 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ros Proto-Oncogene 1, Receptor Tyrosine Kinase

Ensembl ID : ENSSBOG00000026173
Gene Symbol: ROS1
2 Cross references
124 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSSBOG00000015492
Gene Symbol: RAF1
2 Cross references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).